Acne Treatment Market to Grow Gradually by Achieving a Valuation of USD 17.48 billion by 2032 with a CAGR of 5.2% during the Forecast Period

The acne treatment market size is projected to grow from USD 11.62 billion in 2024 to USD 17.48 billion by 2032. As per a report by Fortune Business Insights™ titled “Acne Treatment Market Size, Share & COVID-19 Impact Analysis, By Product (Retinoids, Antibiotics, Isotretinoin, and Others), By Route of Administration (Oral and Topical), By Age Group (10 to 17 Years, 18 to 44 Years, 45 to 64 Years, and 65 Years & Above), By Distribution Channel (Hospital Pharmacies and Retail & Online Pharmacies), and Regional Forecast, 2024-2032”. The market stood at USD 11.09 billion in 2023. It is set to exhibit a CAGR of 5.2% during 2024-2032. 

Huge Loss in Revenue Caused Due to Pandemic Impacted Market Growth Negatively

Due to the outbreak of the COVID-19, the demand for drugs staggered globally due to the decrease in the number of patients owing to stringent lockdown restrictions. Moreover, disrupted supply chains, decreased production, closing of dermatology clinics, redistribution of healthcare expenditure, and other factors affected the sales of drugs during 2020. Hence, the acne treatment market growth witnessed a downfall during COVID-19 pandemic outbreak.

Increasing Prevalence of Acne Globally to Drive the Market Growth

Globally, the occurrence of skin conditions increased considerably. Hence, the number of patients opting for the treatment is increasing rapidly in the developed and developing countries in Asia Pacific, North America, and Europe. The introduction of various products used for the treatment, such as antibiotics in oral and topical forms, retinoids, and isoretinoids, is growing awareness about acne products and available treatment options.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/acne-treatment-market-103361

GlaxoSmithKline plc Signed an Agreement with Eligo BioScience to Foster Market Growth

GlaxoSmithKline plc in an agreement with Eligo BioScience has agreed to make advancements in Eligobiotics for the treatment and prevention of Acne Vulgaris with CRISPR-based therapeutics for strain-specific microbiome modulation.

Competitive Landscape:

Growing Focus on Inorganic Growth Strategies to Drive the Market Growth

The market is divided by a large number of key players delivering various types of drugs. The major companies will have a strong revenue position along with a diversified product portfolio of drugs. The companies with a strong presence in the market are Valeant Pharmaceutical International, Inc. and Botanix Pharmaceuticals, which are expected to aid the market growth of acne treatment.

Notable Industry Development:

• December 2022: Beiersdorf AG acquired a Belgium company, S-Biomedic NV, to strengthen its expertise in the acne treatment industry.

List of the Companies Profiled in the Report:

• Allergan (Ireland)


• Botanix Pharmaceuticals (Australia)


• GALDERMA (Switzerland)


• Bausch Health Companies Inc. (U.S.) 


• GlaxoSmithKline Plc. (U.K.)


• Bayer AG (Germany)


• Johnson & Johnson Services, Inc. (U.S.)


• Pfizer Inc. (U.S.)


• Teva Pharmaceutical Industries Ltd. (Israel)

Further Report Findings:

• North America dominates the acne treatment market share owing to the growing occurrence of acne across the region and the rising concerns related to beauty among the population. Hence, prominent players in the market have introduced new drugs resulting in the increase in demand for medicines in the region.


• Europe is anticipated to record the second largest shareholder owing to the rising patient pool in the region, robust investment in R&D for the drugs used for the treatment of dermatology conditions by the major companies, and increased use of advanced treatment products.

Table of Segmentation: